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The aim of this work was investigation of clinically important amino acid
substitutions of NDM-1 variants. A blaNDM-1 gene was cloned into expression
vector pET100/D-TOPO. The sequence of NDM-1 variants with substituted amino
acids was determined by ClustalW program. A pET100/D-TOPO + blaNDM-1 was
used to generate the alanine mutations at different positions, such as NDM-2
(P28A), NDM-3 (D95A), NDM-4 (M154A), NDM-5 (V88A), NDM-7 (D130A),
and NDM-9 (E152A). The mutant variants were transformed into Escherichia coli
DH5α. Changes in the activities of alanine mutation variants were determined by
E-test. All samples had 32 μg/ml MIC values against ampicillin. The 28th amino acid
mutation sample had the highest MIC value against ceftazidime, whereas decreased
MIC value for piperacillin. It was observed that the resistance to imipenem was
increased in mutant variants D95A, M154A, D130A, and E152A, comparing with
P28A and V88A. It was found that NDM-1 has 0.64 μg/ml and the 130th amino acid
mutation sample has 0.75 μg/ml meropenem MIC value.
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Introduction
New Delhi metallo-β-lactamase-1 (NDM-1) is the most recently discov-
ered Ambler Class B β-lactamase enzyme. NDM-1 was ﬁrst isolated from an
Indian patient living in Sweden in 2008 and it was described in Klebsiella
pneumoniae and Escherichia coli strains [1, 2]. The phenotypic tests performed
showed that both isolates carry carbapenem resistance due to the production of
metallo-β-lactamase (MBL), but the polymerase chain reaction (PCR) analysis
did not detect known MBL genes. Results of the cloning and sequencing studies
have shown that MBL was a new enzyme [1, 3] and it was called NDM-1 [3].
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NDM-2 variant was identiﬁed in 2011 and a single amino acid substitution
was found to be different from NDM-1 [4]. Altogether, 16 variants of NDM-1
with the amino acid changes are recorded in the literature from 2009 to 2015
(http://www.lahey.org/Studies/other.asp). As with other class B β-lactamase,
NDM-1 also contains zinc ion at the active site [5–7]. NDM-1 is able to
hydrolyze all β-lactams except aztreonam, which is a monobactam [6]. Most of
the NDM-1-positive bacteria show resistance to β-lactams, also other drug
classes, and carry resistance mechanisms, such as aminoglycosides and
ﬂuoroquinolones [8–12].
After the discovery of NDM-1, it was observed throughout the world in
many species of bacteria. NDM-1 has been found in Germany, India, England,
Canada, America, Kenya, Israel, South Africa, South Korea, Thailand, many
European countries, and Far East countries, such as China [8, 13–15] so far.
NDM-1 has also been ﬁrst described in Turkey in 2011 [16].
In the study of Iraz et al. [17], NDM-1 was identiﬁed in K. pneumoniae
and the blaNDM-1 was applied in this study. It was cloned into TOPO-100
expression vector and alanine mutations were generated as follows: NDM-2
(P28A), NDM-3 (D95A), NDM-4 (M154A), NDM-5 (V88A), NDM-7
(D130A), and NDM-9 (E152A). Changes in the activities of the alanine
mutation variants were measured by E-test.
Materials and Methods
Detection of blaNDM-1 gene and cloning experiments
blaNDM-1 gene was detected by PCR. Cloning of the blaNDM-1 gene to
expression vector pET100/D-TOPO + blaNDM-1 was ampliﬁed using primers
Ndm_TOPO_Fw: 5′CACCATGGAATTGCCCAATATTATGC-3′ and Ndm_
TOPO_Rw: 5′-TCAGCGCAGCTTGTCGGCCATGC-3′ to obtain the whole
gene sequence. The obtained PCR fragment was puriﬁed using a QIAquick
column (QIAGEN, Courtaboeuf, France), cloned into the pET100/D-
TOPO vector, and transformed into E. coli DH5α (Invitrogen Life Technologies,
Saint Aubin, France). The transformant cells harboring plasmid vectors were
selected on Mueller–Hinton (MH) agar containing ampicillin (50 mg/ml). The
cloned DNA fragment inserted into one of the recombinant plasmids was
sequenced by Macrogen. Sequencing results were analyzed using an alignment
search tool BLAST (http://www.ncbi.nlm.nih.gov/BLAST) and the multiple
sequence alignment program CLUSTALW2 (http://www.ebi.ac.uk/Tools/msa/
clustalw2/).
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Bioinformatics analysis
According to the ofﬁcial classiﬁcation of β-lactamases web page, NDM-1
enzyme has 16 variants. The NDM-1 enzyme amino acid sequences were obtained
from Genbank and amino acid changes were determined using the ClustalW
program. Clinically important amino acids were identiﬁed and site-directed
mutagenesis was performed on NDM-1 enzyme to substitute them. Clinically
important amino acids were evaluated in this study.
Site-directed mutation of the target amino acid
All mutations were completed through blaNDM-1 allele, which was cloned
into the Champion™ pET100/D-TOPO expression vector. All alleles (NDM-2,
NDM-3, NDM-4, NDM-5, NDM-7, and NDM-9) corresponding to the change in
amino acids will be transformed into alanine amino acids by directed mutations
out of the NDM-1 gene. Primers were designed to generate the alanine mutation in
each allele (Table I). A single reaction mixture contained 2 μl of plasmid DNA,
20 pM of each primer, 10 μl of reaction buffer, 3 μl of 25 mM MgCl2, 200 μM of
deoxynucleotide triphosphates, and 1.5 U of Pfu Polymerase (Promega, Madison,
USA) in a ﬁnal volume of 50 μl. All PCR results were analyzed on 1% agarose
containing 0.5 μg/ml ethidium bromide and were subsequently visualized under
UV light. PCR products were cleaned up by PCR-clean up kit (Promega) and DpnI
enzyme digestion was made. After digestion, the samples were transformed into E.
coli DH5α. Plasmids were isolated and submitted to DNA sequence analysis.
Table I. The primers used to generate mutations
Target mutations Primers (5′→3′)
NDM-2_28A_F TTGATGCTGAGCGGGTGCATGGCCGGTGAAATCCGCCCGACGATT
NDM-2_28A_R AATCGTCGGGCGGATTTCACCGGCCATGCACCCGCTCAGCATCAA
NDM-3_95A_F GTGGTCGATACCGCCTGGACCGCTGACCAGACCGCCCAG
NDM-3_95A_R CTGGGCGGTCTGGTCAGCGGTCCAGGCGGTATCGACCAC
NDM-4_154A_F CAGCTTGCCCCGCAAGAGGGGGCGGTTGCGGCGCAACACAGC
NDM-4_154A_R GCTGTGTTGCGCCGCAACCGCCCCCTCTTGCGGGGCAAGCTG
NDM-5_88A_F AGGGATGGCGGCCGCGTGCTGGCGGTCGATACCGCCTGGACCGAT
NDM-5_88A_R ATCGGTCCAGGCGGTATCGACCGCCAGCACGCGGCCGCCATCCCT
NDM-7_130A_F CAGGACAAGATGGGCGGTATGGCCGCGCTGCATGCGGCGGGGATT
NDM-7_130A_R AATCCCCGCCGCATGCAGCGCGGCCATACCGCCCATCTTGTCCTG
NDM-9_152A_F TCGAACCAGCTTGCCCCGCAAGCGGGGATGGTTGCGGCGCAACACAGC
NDM-9_152A_F GCTGTGTTGCGCCGCAACCATCCCCGCTTGCGGGGCAAGCTGGTTCGA
Note: NDM: New Delhi metallo-β-lactamase.
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Sequencing results were analyzed using BLAST (http://www.ncbi.nlm.nih.gov/
BLAST) and CLUSTALW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/).
E-test
The E-test was performed using E-test strips containing cefotaxim, piper-
acillin/tazobactam, cefepime, cefoxitin, piperacillin, ceftazidime, amoxicillin+
clavulanic acid, imipenem, meropenem, and ertapenem, according to the manu-
facturer’s instructions in plates with MH agar.
Results
NDM-type MBL enzyme has 16 variants and 14 of them reached the
nucleotide sequence (Table II). Using speciﬁc primers, the blaNDM-1 gene with
813 base pairs in length was ampliﬁed from K. pneumoniae genome and blaNDM-1
gene was cloned to pET100/D-TOPO vector. Conversion of the targeted amino
acids (P28A, D95A, M154A, V88A, D130A, and E152A) into alanine amino
acid was conﬁrmed by sequence analysis using pET100/D-TOPO +NDM
vectors. The CCC codon encoding the 28th amino acid (proline, P) was
converted into the GCC codon encoding alanine (A) amino acid; the GAT
codon encoding the 95th amino acid (aspartic acid, D) was converted into the
Table II. NDM variants and amino acid changes that cause these variants
Amino acids and positions, which cause alleles of NDM-1
NDM alleles 28 32 36 69 74 88 95 130 152 154 200 222 233
NDM-1 P R G G A V D D E M G G A
NDM-2 A R G G A V D D E M G G A
NDM-3 P R G G A V N D E M G G A
NDM-4 P R G G A V D D E L G G A
NDM-5 P R G G A L D D E L G G A
NDM-6 P R G G A V D D E M G G V
NDM-7 P R G G A V D N E L G G A
NDM-8 P R G G A V D G E L G G A
NDM-9 P R G G A V D D K M G G A
NDM-10 P S D S T V D D E M R G A
NDM-11 P R G G A V D D E V G G A
NDM-12 P R G G A V D D E L G D A
NDM-13 P R G G A V N D E L G G A
NDM-14 P R G G A V D G E M G G A
Note: The elements in italics represent amino acid changes occurring in NDM-1 alleles. NDM: New Delhi
metallo-β-lactamase.
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GCT codon encoding alanine (A) amino acid; the ATG codon encoding the 154th
amino acid (metyonin, M) was converted into the GCG codon encoding alanine
(A) amino acid; the GTG codon encoding the 88th amino acid (valine, V) was
converted into the GCG codon encoding alanine (A) amino acid; the GAC codon
encoding the 130th amino acid (aspartic acid, D) was converted into the GCC
codon encoding alanine (A) amino acid; and the GAG codon encoding the 152th
amino acid (glutamic acid, E) was converted into the GCC codon encoding
alanine (A) amino acid.
Minimum inhibitory concentration (MIC) values were determined by E-test
method. MIC values are shown in Table III. All mutant strains have 32 μg/ml MIC
value for piperacillin/tazobactam except P28A mutant (MIC: 1.5 μg/ml). While
D130A and E152A have 256 μg/ml, P28A and V88A have 0.125 μg/ml and D95A
and M154A have 0.19 μg/ml MIC for cefepime. There are about 2,000-fold
differences between the mutations of D130A and E152A and others (Table III).
D95A and D130A have 2 μg/ml, P28A and E152A have 4 μg/ml, and there are
twofold differences between them for cefoxitin. In addition, there is twofold
difference between M154A (1.5 μg/ml) and V88A (3 μg/ml) for cefoxitin. P28A
has the highest MIC (>2 μg/ml) for ceftazidime. V88A and E152A have 48 μg/ml,
D95A and M154A have 24 μg/ml, and P28A has 16 μg/ml MIC for amoxicillin+
clavulanic acid. MIC of imipenem for D95A is 0.125 μg/ml; 0.094 μg/ml for
M154A, D130A, and E152A; and 0.032 μg/ml for P28A and V88A. There are
twofold differences between P28A and D95A (0.008 μg/ml) and V88A, D130A,
and E152A (0.016 μg/ml).
Discussion
Creating the basic mechanisms of bacterial resistance to β-lactams is
producing hydrolytic enzymes. These hydrolytic enzymes are called β-lactamases
and they break the amide bond in the β-lactam ring of β-lactams [18, 19]. To date,
more than 1,000 β-lactamases were reported [20]. These enzymes are chromosom-
ally encoded or on mobile genetic elements, such as transposons and plasmids.
β-lactamases show too many differences according to their functional, biochemi-
cal, and similarity of amino acid sequences. According to Ambler molecular
classiﬁcation, β-lactamases can be structurally divided into two superfamilies:
serin (classes A, C, and D) and MBLs (class B). Both serine β-lactamases and
MBLs are able to hydrolyze the β-lactams, although catalytic mechanisms are
different. The spread of MBLs among Gram-negative pathogens is a very serious
problem [5]. More importantly, MBLs are carried with other resistance genes that
restrict treatment options with the formation of multiresistance [6].
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Rapid spread of MBL is related to mobile genetic elements, such as
plasmids, transposable elements, and insertion sequences Cas9-like relation-
ship between MBL genes [5, 6]. Spread of earned MBLs is very crucial for
infection control and the treatment of patients [5]. NDM-type of metallo-
β-lactamases has been reported to have 16 variants and they have one or more
amino acid changes between these variants (http://www.lahey.org/Studies/).
Every year, some of the new variants are deﬁned in Enterobacteriaceae.
Accumulation of mutations on the gene takes years and the amount of the
accumulated mutations on a gene that gives information about the gene has a
long history. Currently, there are a few variants of the NDM-type β-lactamase
when compared with other types of β-lactamases, but the number of the
variants in future cannot be predicted or foreseen [21]. Site-directed muta-
genesis experiments on MBL conducted on the results are of great impor-
tance, because occurring variants of increasing antibiotic concentrations
(MICs) contain mutations selected on their ability to remain alive in the
bacterial host. Therefore, experiments with puriﬁed recombinant proteins
increase the understanding about the effects of mutations that confer
resistance [21].
Yıldız et al. [22] have conducted phenotypic tests on carbapenemase-
producing strains (OXA-48 and NDM-1) and they found that CarbaNP and
carbapenem inactivation method tests were suitable for describing carbapenem
producers. In a study, NDM-5 has been shown to increase the MIC values for
ceftazidime, cefotaxime, and cefepime comparing with NDM-1 [23]. In another
study on NDM variant of antibiotic susceptibility proﬁle, an increase in MIC
values against carbapenems has been observed in NDM-5 and NDM-7 [24].
Another work showed that the NDM-producing isolates exhibited high mer-
openem MIC values of 2–4 g/ml [25].
In this study, substitution of valine at the 88th position to alanine,
when compared with NDM-1, appears to give almost similar MIC values. In
this work, NDM enzyme substrate proﬁle differs among NDMs by means of
in vitro assays directed mutation MBL-out made alanine mutation resulting
mutant. The rapid evolution of NDM gene and intercontinental travel and health
tourism role illustrate the global spread of multidrug-resistant organisms.
Because of the rapid spread of NDM gene, it is expected that more will be
discovered in future.
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